Results 211 to 220 of about 26,042 (243)
Some of the next articles are maybe not open access.
2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources
Imatinib mesylate-induced acute hepatotoxicity
Journal of Oncology Pharmacy Practice, 2023Introduction Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. Case report We report a 51-year-
Imen Frikha +5 more
openaire +2 more sources
Imatinib Mesylate (Gleevec) Hepatotoxicity
Digestive Diseases and Sciences, 2007Imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ), formerly known as STI571, is a specific inhibitor of BCR-ABL tyrosine kinase. It is widely used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and c-kit (CD117) positive unresectable and/or metastatic malignant ...
Ayse L, Mindikoglu +5 more
openaire +2 more sources
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2006Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Strebhardt, K., Ullrich, A.
openaire +3 more sources
Kinase drug discovery 20 years after imatinib: progress and future directions
Nature Reviews Drug Discovery, 2021Philip Cohen +2 more
exaly
2015
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Imatinib Mesylate Induced Erythroderma.
The Journal of the Association of Physicians of India, 2019Imatinib, a specific tyrosine kinase inhibitor is a new anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is well tolerated with few side effects. Commonest adverse events are maculopapular eruptions and periorbital edema were reported. Severe adverse reactions are seen in 5% of patients.
Snehal, Lunge, Rohan, Bhise
openaire +1 more source
Improving the outcome for children with cancer: Development of targeted new agents
Ca-A Cancer Journal for Clinicians, 2015Peter C Adamson
exaly
Immunological off-target effects of imatinib
Nature Reviews Clinical Oncology, 2016Laurence Zitvogel +2 more
exaly